公司业绩与股价表现 - 公司第一季度财报表现强劲，包括收入增长和乐观的业绩指引 [1] - 公司与诺和诺德(Novo Nordisk)达成重要合作，进一步推动股价上涨 [1] - 股价在财报发布后持续攀升，过去一个月上涨100%，年初至今涨幅超过100% [2] - 股价目前为51.12美元，远高于8日、20日、50日和200日均线，呈现强劲上涨趋势 [3] 市场情绪与空头挤压 - 空头头寸仍高达流通股的33%，高股价加剧空头挤压风险 [2] - 技术面和基本面均不支持看空观点，可能引发经典的空头挤压行情 [3] - 空头面临亏损，部分可能选择平仓以避免进一步损失 [3] 业务发展 - 公司不再仅专注于减肥药物，业务范围扩展可能进一步推动增长 [4] - 此前FDA信号显示司美格鲁肽短缺问题结束，但公司股价仍逆势上涨 [2]

投资策略 - 长期增长投资者专注于寻找创新公司 这些公司致力于改善世界 [1] - 投资策略围绕寻找"分歧股票" 即具有强大基本面、长期增长潜力但价格低迷的颠覆性公司 [1] 持仓披露 - 分析师持有HIMS股票的多头头寸 通过股票所有权、期权或其他衍生工具 [1]

公司业绩表现 - 第一季度营收5.86亿美元，同比增长111%，远超5.3-5.5亿美元的预期[5] - 每月在线用户收入84美元，同比增长53%，订阅用户数增长38%至240万[5] - 使用至少一项个性化订阅服务的用户激增136%至140万，占总用户60%[5] - 调整后EBITDA达9100万美元，同比增长182%，调整后EPS为0.20美元，远超分析师预期的0.12美元[11] - 运营现金流增长322%至1.09亿美元，自由现金流增长321%至5000万美元[11] 业务发展策略 - 个性化服务成为重点战略，80%皮肤科患者使用个性化方案，计划扩展到数千种治疗方案[6] - 减肥药物业务预计今年贡献7.25亿美元收入，非GLP-1类减肥药物业务仍保持30%增长[7] - 与诺和诺德合作销售Wegovy品牌减肥药，扩大产品组合[8] - 计划将个性化服务扩展到长寿和预防保健领域[6] - 未来增长将来自个性化服务、新专科领域和国际扩张[13] 财务指标变化 - 毛利率下降900个基点至73%，主要受GLP-1药物影响，但预计下季度将环比改善[9] - 营销支出激增77%至2.31亿美元，占营收比例从47%降至39%[10] - 维持2025年23-24亿美元营收预期，上调调整后EBITDA预期至2.95-3.35亿美元[12] - 首次给出2030年预测：营收至少65亿美元，调整后EBITDA至少13亿美元，2026-2030年CAGR约22%[13] 市场反应与争议 - 股价年初至今上涨108%，但较年内高点下跌27%，空头比例超过25%[1][2] - 投资者对公司看法分歧：看好收入增长和盈利能力改善，担忧毛利率下降和高营销支出[15] - 公司进入利润率较低的减肥药业务，但整体毛利金额增长显著[16]

Hims & Hers Health (NYSE: HIMS ) has recently published their Q1 2025 earnings , which showed impressive growth metrics as well as ambitious guidance for 2030. When underlying the management's guidance, the company seems to beGerman Buy-Hold-Check investor. With a master's degree in engineering and management, I am able to understand, quantify, and interpret both the economics and (to some point) the technology of companies.Analyst’s Disclosure: I/we have a beneficial long position in the shares of HIMS eit ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...

投资组合配置 - 投资组合中股票与看涨期权各占50% [1] - 投资时间框架通常为3-24个月 [1] 投资风格与策略 - 采用逆向投资风格 偏好高风险且流动性差的期权交易 [1] - 重点关注因非经常性事件导致近期抛售的股票 尤其当内部人士以新低价买入时 [1] - 筛选范围覆盖数千只美国股票 偶尔涉及新兴市场公司 [1] 分析方法 - 运用基本面分析评估公司健康状况 包括杠杆水平和财务比率与行业均值/中位数的对比 [1] - 对抛售后买入股票的内部人士进行专业背景调查 [1] - 通过技术分析优化买卖点 主要使用周线图上的多色支撑/阻力线 偶尔绘制多色趋势线 [1] 筛选标准 - 优先选择内部人士在股价下跌后增持的公司 [1] - 结合定量与定性分析进行交叉验证 [1]

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

财务表现 - 公司一季度净利润同比飙升300% 超出市场预期 [1] - 股价当日上涨9 9%至46 06美元 抹去盘前跌幅 [1] - 尽管发布悲观业绩指引 仍获四家机构上调目标价 其中Leerink Partners将目标价从40美元调至42美元 [1] 期权交易 - 当日期权交易量达26 7万份看涨合约和18 8万份看跌合约 为日均交易量的6倍 [2] - 最活跃合约为5月9日到期、行权价45美元的周看涨期权 其次为同系列50美元看涨期权 且两个合约均有新开仓 [2] 技术走势 - 股价突破自3月初以来压制价格的40美元阻力位 创2月以来新高 [3] - 连续四个交易日上涨 站稳60日均线上方 年内涨幅达296% [3] 做空压力 - 近两个报告期内空头仓位增加10 8% 目前做空股数达6088万股 占流通股的31 9% [7] - 高比例空头仓位显示潜在轧空风险 若空头回补可能推动股价进一步上涨 [7]

Monday evening was big for Hims & Hers Health, Inc. (NYSE: HIMS ), I can't lie, their turnaround impressed me. They somehow managed to beat expectations for earnings , keep a healthyI’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve aroun ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...